Abstract
Background
Hepatitis C virus (HCV) treatment can reduce the incidence of future infections through removing opportunities for onward transmission. This benefit is not captured in conventional cost-effectiveness evaluations of treatment and is particularly relevant in patient groups with a high risk of transmission, such as those people who inject drugs (PWID), where the treatment rates have been historically low. This study aimed to quantify how reduced HCV transmission changes the cost-effectiveness of new direct-acting antiviral (DAA) regimens as a function of treatment uptake rates.
Methods
An established model of HCV disease transmission and progression was used to quantify the impact of treatment uptake (10–100%), within the PWID population, on the cost-effectiveness of a DAA regimen versus pre-DAA standard of care, conducted using daclatasvir plus sofosbuvir in the UK setting as an illustrative example.
Results
The consequences of reduced disease transmission due to treatment were associated with additional net monetary benefit of £24,304–£90,559 per patient treated at £20,000/QALY, when 10–100% of eligible patients receive treatment with 100% efficacy. Dependent on patient genotype, the cost-effectiveness of HCV treatment using daclatasvir plus sofosbuvir improved by 36–79% versus conventional analysis, at 10–100% treatment uptake in the PWID population.
Conclusions
The estimated cost-effectiveness of HCV treatment was shown to improve as more patients are treated, suggesting that the value of DAA regimens to the NHS could be enhanced by improved treatment uptake rates among PWID. However, the challenge for the future will lie in achieving increased rates of treatment uptake, particularly in the PWID population.
Similar content being viewed by others
References
Shepard, C.W., Finelli, L., Alter, M.J.: Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5(9), 558–567 (2005)
Hatzakis, A., Chulanov, V., Gadano, A.C., et al.: The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm—volume 2. J. Viral Hepat. 22(Suppl 1), 26–45 (2015)
Public Health England, Health Protection Scotland, Public Health Wales, Public Health Agency: Hepatitis C in the UK: 2014 report. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/337115/HCV_in_the_UK_2014_24_July.pdf (2014). Accessed Jan 2015
Public Health England, Health Protection Scotland, Public Health Wales, Public Health Agency: Shooting up: infections among people who inject drugs in the United Kingdom 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/370707/Shooting_Up_2014.pdf (2014). Accessed Jan 2015
Afdhal, N.H.: Hepatitis C viral infection in difficult-to-treat populations: an overview. Clin. Liver Dis. 1(3), 63–64 (2012)
Kemmer, N., Neff, G.W.: Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int. 27(10), 1297–1310 (2007)
European Association for the Study of the Liver: EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 60(2), 392–420 (2014)
Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al.: Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 370(3), 211–221 (2014)
Lawitz, E., Mangia, A., Wyles, D., et al.: Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368(20), 1878–1887 (2013)
Gilead Sciences International Ltd: Summary of product characteristics. Sovaldi® 400 mg film-coated tablets. Updated June 2014. http://www.medicines.org.uk/emc/medicine/28539/SPC/Sovaldi+400+mg+film+coated+tablets/ (2014). Accessed Feb 2015
Janssen-Cilag Ltd: Summary of product characteristics. OLYSIO® 150 mg hard capsules. https://www.medicines.org.uk/emc/medicine/28888 (2014). Accessed Feb 2015
Scottish Medicines Consortium: Daclatasvir 30 and 60 mg film-coated tablets (Daklinza®). SMC No. 1002/14. https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1002_14_daclatasvir_Daklinza/daclatasvir_Daklinza (2014). Accessed Jan 2015
Hagan, L.M., Sulkowski, M.S., Schinazi, R.F.: Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 60(1), 37–45 (2014)
Petta, S., Cabibbo, G., Enea, M., et al.: Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 59(5), 1692–1705 (2014)
Gordon, S.C., Pockros, P.J., Terrault, N.A., et al.: Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 56(5), 1651–1660 (2012)
Westbrook, R.H., Dusheiko, G.: Natural history of hepatitis C. J. Hepatol. 61(1), S58–S68 (2014)
National Institute for Health and Care Excellence: NICE technology appraisal guidance [TA331]. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C. https://www.nice.org.uk/guidance/ta331 (2015). Accessed 16 Mar 2016
National Institute for Health and Care Excellence: NICE technology appraisal guidance [TA364]. Daclatasvir for treating chronic hepatitis C. https://www.nice.org.uk/guidance/ta364 (2015). Accessed 16 Mar 2016
National Institute for Health and Care Excellence: NICE technology appraisal guidance [TA330]. Sofosbuvir for treating chronic hepatitis C. https://www.nice.org.uk/guidance/ta330 (2015). Accessed 16 Mar 2016
National Institute for Health and Care Excellence: NICE technology appraisal guidance [TA363]. Ledipasvir–sofosbuvir for treating chronic hepatitis C. https://www.nice.org.uk/guidance/ta363 (2015). Accessed 16 Mar 2016
National Institute for Health and Care Excellence: NICE technology appraisal guidance [TA365]. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C. https://www.nice.org.uk/guidance/ta365 (2015). Accessed 16 Mar 2016
National Institute for Health and Care Excellence: Single technology appraisal. Daclatasvir for treating chronic hepatitis C: final scope. http://www.nice.org.uk/guidance/gid-tag487/documents/hepatitis-c-chronic-daclatasvir-final-scope2 (2014). Accessed Feb 2015
National Institute for Health and Care Excellence: Single technology appraisal. Ledipasvir–sofosbuvir for treating chronic hepatitis C: final scope. http://www.nice.org.uk/guidance/gid-tag484/documents/hepatitis-c-chronic-ledipasvirsofosbuvir-final-scope2 (2014). Accessed Feb 2015
World Health Organization: Guidelines for the screening, care and treatment of persons with hepatitis C infection. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ (2014). Accessed Jan 2015
Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M.: Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J. Hepatol. 54(6), 1137–1144 (2011)
Harris, R.J., Thomas, B., Griffiths, J., et al.: Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J. Hepatol. 61(3), 530–537 (2014)
Martin, N.K., Foster, G.R., Vilar, J., et al.: HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J. Viral Hepat. 22(4), 399–408 (2015)
Cousien, A., Tran, V.C., Deuffic-Burban, S., Jauffret-Roustide, M., Dhersin, J.S., Yazdanpanah, Y.: Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. J. Viral Hepat. 22(3), 213–229 (2015)
Martin, N.K., Vickerman, P., Grebely, J., et al.: Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58(5), 1598–1609 (2013)
Hellard, M.E., Jenkinson, R., Higgs, P., et al.: Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med. J. Aust. 196(10), 638–641 (2012)
Duberg, A.S., Blach, S., Falconer, K., Kaberg, M., Razavi, H., Aleman, S.: The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand. J. Gastroenterol. 50(2), 233–244 (2015)
Martin, N.K., Vickerman, P., Dore, G.J., et al.: Prioiritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J. Hepatol. 65(1), 17–25 (2016)
Bennett, H., McEwan, P., Sugrue, D., Kalsekar, A., Yuan, Y.: Assessing the long-term impact of treating hepatitis C virus (HCV)-Infected people who inject drugs in the UK and the relationship between treatment uptake and efficacy on future infections. PLoS One 10(5), e0125846 (2015)
McEwan, P., Kim, R., Yuan, Y.: Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl. Health Econ. Health Policy 11(1), 53–63 (2013)
McEwan, P., Ward, T., Chen, C.-J., et al.: Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Reg. Issues 3, 5–11 (2014)
McEwan, P., Ward, T., Yuan, Y., Kim, R., L’Italien, G.: The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 58(1), 54–64 (2013)
McEwan, P., Ward, T., Bennett, H., et al.: Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 10(1), e0117334 (2015)
Thein, H.H., Yi, Q., Dore, G.J., Krahn, M.D.: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48(2), 418–431 (2008)
Kanwal, F., Kramer, J.R., Ilyas, J., Duan, Z., El-Serag, H.B.: HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US Veterans with HCV. Hepatology 60(1), 98–105 (2014)
Townsend, R., McEwan, P., Kim, R., Yuan, Y.: Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 14(8), 1068–1077 (2011)
Shepherd, J., Jones, J., Hartwell, D., Davidson, P., Price, A., Waugh, N.: Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess. 11(11), 1–205 (2007)
Pearlman, B.L., Traub, N.: Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin. Infect. Dis. 52(7), 889–900 (2011)
Akhtar, E., Manne, V., Saab, S.: Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver. Int. 35(1), 30–36 (2014)
Im, G.Y., Dieterich, D.T.: Direct-acting antiviral agents in patients with hepatitis C cirrhosis. Gastroenterol. Hepatol. (N. Y.) 8(11), 727–765 (2012)
Personal Social Services Research Unit: Unit costs of Health and Social Care 2013. http://www.pssru.ac.uk/project-pages/unit-costs/2013/ (2013). Accessed Oct 2015
Public Health England: Commissioning template for estimating HCV prevalence by DAT and numbers eligible for treatment. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HepatitisC/EpidemiologicalData/ (2014). Accessed Feb 2015
Public Health England, Health Protection Scotland, Public Health Wales, Public Health Agency: Hepatitis C in the UK: 2013 report. http://www.hpa.org.uk/Publications/InfectiousDiseases/BloodBorneInfections/HepatitisCInTheUK/1307HepatitisCintheUK2013report/ (2013). Accessed Feb 2015
National Institute for Health and Care Excellence: Guide to the methods of technology appraisal 2013. http://www.nice.org.uk/article/pmg9 (2013). Accessed Feb 2015
Leidner, A.J., Chesson, H.W., Xu, F., Ward, J.W., Spradling, P.R., Holmberg, S.D.: Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 61(6), 1860–1869 (2015)
Leleu, H., Blachier, M., Rosa, I.: Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J. Viral Hepat. 22(4), 376–383 (2015)
The All-Party Parliamentary Hepatology Group: In the dark: an audit of hospital hepatitis C services across England. http://www.appghep.org.uk/wp-content/uploads/2014/02/In-The-Dark-An-audit-of-hospital-hepatitis-C-services-across-England-APPHG-2010.pdf (2010). Accessed Feb 2015
Arain, A., Robaeys, G.: Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J. Gastroenterol. 20(36), 12722–12733 (2014)
Innes, H., Goldberg, D., Dillon, J., Hutchinson, S.J.: Strategies for the treatment of hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? Gut. 64(11), 1800–1809 (2014)
Hope, V.D., Hickman, M., Ngui, S.L., et al.: Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat. 18(4), 262–270 (2011)
Sweeting, M.J., Hope, V.D., Hickman, M., et al.: Hepatitis C infection among injecting drug users in England and Wales (1992–2006): there and back again? Am. J. Epidemiol. 170(3), 352–360 (2009)
Kimber, J., Copeland, L., Hickman, M., et al.: Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 341, c3172 (2010)
Hickman, M., Hope, V., Coleman, B., et al.: Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J. Public Health (Oxf.) 31(3), 374–382 (2009)
Cornish, R., Macleod, J., Strang, J., Vickerman, P., Hickman, M.: Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 341, c5475 (2010)
Health Protection Scotland and University of the West of Scotland: Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV, HIV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2007. http://www.hps.scot.nhs.uk/search/atozdetail.aspx?source=8&subject=93 (2008). Accessed Feb 2015
Allen, E.J., Palmateer, N.E., Hutchinson, S.J., Cameron, S., Goldberg, D.J., Taylor, A.: Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int. J. Drug Policy 23(5), 346–352 (2012)
University of the West of Scotland: The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and injecting risk behaviours among people who inject drugs attending injecting provision services in Scotland, 2008/2009 and 2010. http://www.documents.hps.scot.nhs.uk/bbvsti/hepatitis-c/publications/nesi-needle-exchange.pdf (2011). Accessed Feb 2015
Vickerman, P., Martin, N., Turner, K., Hickman, M.: Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 107(11), 1984–1995 (2012)
Kemp, P.A., Neale, J., Robertson, M.: Homelessness among problem drug users: prevalence, risk factors and trigger events. Health Soc. Care Community 14(4), 319–328 (2006)
Innes, H.A., Hutchinson, S.J., Allen, S., et al.: Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur. J. Gastroenterol. Hepatol. 24(6), 646–655 (2012)
Micallef, J.M., Kaldor, J.M., Dore, G.J.: Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 13(1), 34–41 (2006)
Mondelli, M.U., Cerino, A., Cividini, A.: Acute hepatitis C: diagnosis and management. J. Hepatol. 42(1), S108–S114 (2005)
Turner, K.M.E., Hutchinson, S., Vickerman, P., et al.: The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106(11), 1978–1988 (2011)
Aspinall, E.J., Corson, S., Doyle, J.S., et al.: Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin. Infect. Dis. 57(suppl 2), S80–S89 (2013)
Jacobson, I.M., McHutchison, J.G., Dusheiko, G., et al.: Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364(25), 2405–2416 (2011)
Poordad, F., McCone Jr., J., Bacon, B.R., et al.: Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195–1206 (2011)
National Institute for Health and Care Excellence: Technology appraisal TA106: peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. http://guidance.nice.org.uk/TA106 (2006). Accessed Feb 2015
Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H.: Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health. Technol. Assess. 10(21), 1–113, iii (2006)
Grieve, R., Roberts, J., Wright, M., et al.: Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 55(9), 1332–1338 (2006)
Martin, N.K., Vickerman, P., Miners, A., et al.: Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55(1), 49–57 (2012)
National Institute for Health and Care Excellence: Technology appraisal 252. Telaprevir for the treatment of genotype 1 chronic hepatitis C. Updated June 2014. http://www.nice.org.uk/ta252 (2012). Accessed Feb 2015
Personal Social Services Research Unit: Unit Costs of Health and Social Care. http://www.pssru.ac.uk/project-pages/unit-costs/2014/index.php (2014). Accessed Mar 2015
Haymarket Media Group Ltd: Monthly Index of Medical Specialities (MIMS). http://www.mims.co.uk/ (2015) Accessed Feb 2015
Bristol-Myers Squibb Pharmaceuticals Ltd: Final clinical study report AI444040 [data on file]. (2013)
Hadziyannis, S.J., Sette Jr., H., Morgan, T.R., et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346–355 (2004)
Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al.: All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61(4), 1127–1135 (2015)
Acknowledgements
This study was funded by an unrestricted grant from Bristol-Myers Squibb Pharmaceuticals Ltd.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bennett, H., Gordon, J., Jones, B. et al. Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. Eur J Health Econ 18, 1001–1011 (2017). https://doi.org/10.1007/s10198-016-0844-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-016-0844-8